retatrutide sweden | 2381089-83-2 | FR04570 Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

Mazdutide appears to produce side effects that are real but manageable enough that almost nobody stops treatment

Who must avoid it entirely in the class framing: anyone pregnant or breastfeeding, anyone with the personal/family MTC or MEN 2 history above, and anyone with prior serious hypersensitivity to a GLP-1 agonist

Many prescribers recommend transitioning to a maintenance dose to support your continued success beyond GLP-1 treatment

Liraglutide (Victoza, Saxenda) Approved for obesity at higher doses, typically results in 57% weight loss

In many ways, Wegovy is simply a higher-dose version of Ozempic, as they both contain the same active ingredient

Retatrutide, developed by Eli Lilly, represents a paradigm shift by simultaneously activating GIP, GLP-1, and GCG receptors, leveraging their synergistic effects to improve glycemic control, reduce body weight, and enhance lipid metabolism